Evaluating Patients With Abnormal Levels of Gastric Acid
NCT ID: NCT00001240
Last Updated: 2008-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
OBSERVATIONAL
1989-01-31
2004-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Depending on the patient's present condition further diagnostic testing may be required to achieve a diagnosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gastric Ultrasound Versus Gastroscopic Aspiration
NCT07292935
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
NCT04661215
Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms
NCT07250308
Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer
NCT04660058
Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea
NCT02184910
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Ciarleglio CA, Cornelius MJ, Jensen RT, Gardner JD. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):939-44. doi: 10.1016/s0016-5085(85)80011-1.
Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):1026-33. doi: 10.1016/s0016-5085(85)80024-x.
Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD, Jensen RT. Famotidine in the therapy of gastric hypersecretory states. Am J Med. 1986 Oct 24;81(4B):49-59. doi: 10.1016/0002-9343(86)90600-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
89-DK-0005
Identifier Type: -
Identifier Source: secondary_id
890005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.